SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Unquoted Biotechs

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates2/6/2006 10:56:20 AM
  Read Replies (1) of 253
 
Noodling around, came across this cautionary tale (somewhat old, but I lost track of a lot of stuff in the second half of 2005...) -

Oxford Technology Venture Capital Trust plc

Interim Statement

For the period

1 March 2005 to 31 August 2005

Statement on behalf of the Board

Net Assets per share at 31 August 2005 were £0.87, £0.94 on 28 Feb 2005 and
£1.26 on 31 August 2004. The major reason for the fall in net asset value has
been the fall in value of the holding in Avidex, which has been written down to
just £4,305, compared to £300,000 (cost) at 28 Feb 2005, and £1.3m a year ago.

The reason for this dramatic fall is that when the large Venture Capitalists
invested in 2002, they did so by means of special shares with price protection,
and then later with high interest loans. The consequence is very large
dilution for OT1 and all early shareholders...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext